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• There was no statistically significant difference in 
demographics between groups
• Group 1 patients had a greater length of stay than group 2 
patients
• There was a statistically significant difference in 30-day 
readmission rates between groups
• The average diuretic dose was similar between groups 
• Patients in group 1 received additional fluids from antibiotic 
therapy
• Sodium content from antibiotic therapy fluid was negligible
• Limitations:
- Small sample size
- Retrospective chart review
- Patients may have been readmitted to another hospital
- Procalcitonin level was not drawn for all patients
- Specialty consultation may have differed between groups
• Amount of fluids received from antibiotics did not have an 
effect on diuretic therapy 
• Unnecessary antibiotic therapy may lead to increased 
hospital length of stay and higher readmission rates
• Due to the small sample size of this study, future studies 
should be conducted to further evaluate the effect of IV 
antibiotic therapy in patients experiencing heart failure 
exacerbations
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Approximately 5.7 million adults in the United States live with heart 
failure and about 50% succumb to the disease within 5 years1
It is one of the most common causes of hospitalizations due to risk 
of exacerbation2
There are similarities in the clinical presentation of acute 
decompensated heart failure (ADHF) and community-acquired 
pneumonia (CAP)3
Treatment for both conditions is often initiated, however, the 
additional fluid volume and sodium provided by the intravenous 
(IV) antibiotics can be detrimental to these patients4
The purpose of this study is to evaluate the impact of inappropriate IV 
antibiotic therapy on patients admitted for ADHF
Primary Objective
• Compare the length of stay in patients who received IV antibiotic 
therapy versus patients who did not 
Secondary Objectives
• Determine the total daily dose of diuretics received
• Compare 30-day readmission rates between the two groups 
• Determine the total days of antibiotic therapy and total volume of 
IV fluids received from IV antibiotics
• A retrospective review of 113 patients admitted from July 1st, 
2017 to August 31st, 2019
• Patients were classified into 2 groups:
• Group 1: patients with ADHF who received IV antibiotics
• Group 2: patients with ADHF who did not receive IV 
antibiotics
• Inclusion criteria:
• Age ≥ 18 years
• Confirmed diagnosis of ADHF
• Exclusion criteria:
• Age < 18 years, pregnancy, active infection, procalcitonin
> 0.25 ng/mL, hospital-acquired infection, antibiotic use 
prior to admission, or radiographic evidence of pneumonia
• SPSS software was used for statistical analysis
• P-value < 0.05 was considered statistically significant 
DISCUSSION
Baseline Characteristic
Group 1
(n=19)
Group 2
(n= 56)
P-value
Age (Mean, SD) 80.3 (13.2) 74.7 (16.6) 0.187
Gender (n, %)
0.521Female 8 (42.1) 19 (33.9)
Male 11 (57.9) 37 (66.1)
Race (n, %)
0.828
Black 2 (10.5) 8 (14.3)
Hispanic 13 (68.4) 34 (60.7)
White 4 (21.1) 14 (25.0)
Marital Status (n, %)
0.677
Divorced/Separated 3 (15.8) 7 (12.5)
Married 6 (31.6) 23 (41.1)
Single 4 (21.0) 15 (26.8)
Widowed 6 (31.6) 11 (19.6) 
Figure 1: Primary Outcome- Length of Stay (Days)
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Table 2: Secondary Outcomes 
Group 1 
(n=19)
Group 2
(n=56)
P-value
Readmission Rate (n, %) 8 (42.1) 7 (12.5) 0.005
Furosemide Equivalent 
Dose in mg (Mean, SD)
220 (139.4) 214.7 (147.3) 0.732
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Additional Secondary Outcomes for Group 1:
• Days of antibiotic therapy (median, IQR): 2 (2)
• Volume in mL of IV fluid from antibiotics (mean, SD): 592 (530)
Table 1: Demographics
